English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In the present study, we investigated the association between susceptible genetic variants to age-related macular degeneration (AMD) and response to as-needed intravitreal aflibercept injection (IAI) therapy for exudative AMD including both typical neovascular AMD and polypoidal choroidal vasculopathy (PCV) over 12-months. A total of 234 patients with exudative AMD were initially treated with 3 monthly IAI and thereafter as-needed IAI over 12 months. Seven variants of 6 genes including  ARMS2  A69S (rs10490924),  CFH  (I62V:rs800292 and rs1329428),  C2-CFB-SKIV2L (rs429608),  C3  (rs2241394),  CETP  (rs3764261) and  ADAMTS-9  (rs6795735) were genotyped for all participants using TaqMan technology. After adjusting for age, gender, baseline BCVA and AMD subtype, A (protective) allele of  C2-CFB-SKIV2L  rs429608 was associated with visual improvement at 12-month (P = 0.003). Retreatment was associated with T(risk) allele of  ARMS2  A69S (P = 2.0 × 10 −4 ; hazard ratio: 2.18:95%CI: 1.47-3.24) and C(risk) allele of  CFH  rs1329428 (P = 2.0 × 10 −3 ; hazard ratio: 1.74:95%CI: 1.16–2.59) after adjusting for the baseline confounders. The need for additional injections was also associated with T allele of  ARMS2  A69S (P = 1.0 × 10 −5 ) and C allele of  CFH  rs1329428 (P = 3.0 × 10 −3 ) after adjusting for the baseline confounders. The variants of  ARMS2  and  CFH are  informative for both physicians and patients to predict recurrence and to quantify the need for additional injections.

scientific reports

Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy